- PhD, Wuhan University, 2004
Education & Training
Mechanisms of brain tumor evolution through crosstalk between tumor cells and the surrounding brain microenvironment
Dr. Hu’s research aims to understand the cellular and molecular mechanisms of brain tumor evolution, and to develop new therapies for these devastating diseases. His areas of special interest include oncobiology of glioma and medulloblastoma; cancer stem cells; tumor cell plasticity and the tumor microenvironment; functional cancer genomics; the relationship between brain developmental trajectory and tumorigenesis in pediatric brain cancers; mechanisms of tumor initiation, progression, treatment-resistance, and metastasis/recurrence; brain tumor immunotherapy; translational research in druggable target and predictive biomarker discovery.
Selected Publications (* co-first author, # correspondence author):
View Dr. Hu's full list of publications from PubMed
Srivastava R, Labani-Motlagh A, Chen A, Bohorquez JA, Qin B, Dodda M, Yang F, Ansari D, Patel S, Ji H, Trasti S, Chao Y, Patel Y, Zou H, Hu B#, Yi G. Development of a human glioblastoma model using humanized DRAG mice for immunotherapy. Antibody Therapeutics, Volume 6, Issue 4, October 2023, Pages 253–264.
Zheng C, Wei Y, Zhang Q, Sun M, Wang Y, Hou J, Zhang P, Lv X, Su D, Jiang Y, Gumin J, Sahni N, Hu B, Wang W, Chen X, McGrail DJ, Zhang C, Huang S, Xu H, Chen J, Lang FF, Hu J, Chen Y. Multiomics analyses reveal DARS1-AS1/YBX1-controlled posttranscriptional circuits promoting glioblastoma tumorigenesis/radioresistance. Sci Adv. 2023 Aug 4;9(31):eadf3984. doi: 10.1126/sciadv.adf3984. Epub 2023 Aug 4.
Nisnboym M, Vincze SR, Xiong Z, Sneiderman CT, Raphael RA, Li B, Jaswal AP, Sever RE, Day KE, LaToche JD, Foley LM, Karimi H, Hitchens TK, Agnihotri S, Hu B, Rajasundaram D, Anderson CJ, Blumenthal DT, Pearce TM, Uttam S, Nedrow JR, Panigrahy A, Pollack IF, Lieberman FS, Drappatz J, Raphael I, Edwards WB, Kohanbash G. Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival Following Immunotherapy in Murine Glioblastoma. Cancer Res Commun. 2023 Jul 6;3(7):1173-1188. doi: 10.1158/2767-9764.CRC-22-0434. eCollection 2023 Jul.
Zou H, Poore B, Brown EE, Qian J, Xie B, Asimakidou E, Razskazovskiy V, Ayrapetian D, Sharma V, Xia S, Liu F, Chen A, Guan Y, Li Z, Wanggou S, Saulnier O, Ly M, Fellows-Mayle W, Xi G, Tomita T, Resnick AC, Mack MC, Raabe EH, Eberhart CG, Sun D, Stronach BE, Agnihotri S, Kohanbash G, Lu S, Herrup K, Rich JN, Gittes GK, Broniscer A, Hu Z, Li X, Pollack IF, Friedlander RM, Hainer SJ, Taylor MD, Hu B#. A neurodevelopmental epigenetic program mediated by SMARCD3-DAB1-Reelin signaling is hijacked to promote metastatic dissemination of medulloblastoma. Nature Cell Biology, 25, pages 493–507 (2023).
Wu M, Wu L, Wu W, Zhu M, Li J, Wang Z, Li J, Ding R, Liang Y, Li L, hang T, Huang B, Cai Y, Li K, Lu Li, Zhang R, Hu B, Lin F, Wang X, Zheng S, Chen J, You Y, Jiang T, Zhang J, hen H, and Wang Q. Phagocytosis of glioma cells enhances the immunosuppressive phenotype of bone marrow-derived macrophages. Cancer Res. Jan 09, 2023. DOI: 10.1158/0008-5472.can-22-1570.
Wu L, Wu W, Zhang J, Zhao Z, Li L, Zhu M, Wu M, Wu F, Zhou F, Du Y, Chai RC, Zhang W, Qiu X, Liu Q, Wang Z, Li J, Li K, Chen A, Jiang Y, Xiao X, Zou H, Srivastava R, Zhang T, Cai Y, Liang Y, Huang B, Zhang R, Lin F, Hu L, Wang X, Qian X, Lv S, Hu B, Zheng, S, Hu Z, Shen H, You Y, Verhaak RGW, Jiang T, Wang Q. Natural coevolution of tumor and immunoenvironment in glioblastoma. Cancer Discovery. 2022 Dec 2;12(12):2820-2837. doi: 10.1158/2159-8290.CD-22-0196.
Golbourn BJ, Halbert ME, Halligan K, Varadharajan S, Krug B, Mbah NE, Kabir N, Stanton AJ, Locke AL, Casillo SM, Zhao Y, Sanders LM, Cheney A, Mullett SJ, Chen A, Wassell M, Andren A, Perez J, Jane EP, Premkumar DRD, Koncar RF, Mirhadi S, McCarl LH, Chang YF, Wu YL, Gatesman TA, Cruz AF, Zapotocky M, Hu B, Kohanbash G, Wang X, Vartanian A, Moran MF, Lieberman F, Amankulor NM, Wendell SG, Vaske OM, Panigrahy A, Felker J, Bertrand KC, Kleinman CL, Rich JN, Friedlander RM, Broniscer A, Lyssiotis C, Jabado N, Pollack IF, Mack SC, Agnihotri S. Loss of MAT2A compromises methionine metabolism and represents a vulnerability in H3K27M mutant glioma by modulating the epigenome. Nat Cancer, 2022 April 14. doi: 10.1038/s43018-022-00348-3.
Raphael I, Kumar R, McCarl LH, Shoger K, Wang L, Sandlesh P, Sneiderman CT, Allen J, Zhai S, Campagna ML, Foster A, Bruno TC, Agnihotri S, Hu B, Castro BA, Lieberman FS, Broniscer A, Diaz AA, Amankulor NM, Rajasundaram D, Pollack IF, Kohanbash G. TIGIT and PD-1 immune checkpoint pathways are associated with patient outcome and anti-tumor immunity in GBM. Front Immunol. 2021 May 7; 12:637146. doi: 10.3389/fimmu.2021.637146. eCollection 2021.
Arabzade A, Zhao Y, Varadharajan S, Chen HC, Jessa S, Rivas B, Stuckert AJ, Solis M, Kardian A, Tlais D, Golbourn BJ, Stanton AJ, Chan YS, Olson C, Karlin KL, Kong K, Kupp R, Hu B, Injac SG, Ngo M, Wang PR, De Leon LA, Sahm F, Kawauchi D, Pfister SM, Lin CY, Hodges HC, Singh I, Westbrook TF, Chintagumpala MM, Blaney SM, Parsons DW, Pajtler KW, Agnihotri S, Gilbertson RJ, Yi J, Jabado N, Kleinman CL, Bertrand KC, Deneen B, Mack SC. ZFTA-RELA Dictates Oncogenic Transcriptional Programs to Drive Aggressive Supratentorial Ependymoma. Cancer Discov. 2021 Sep;11(9):2200-2215. doi: 10.1158/2159-8290.CD-20-1066. Epub 2021 Mar 19. PMID: 33741710.
Chen A, Jiang Y, Li Z, Wu L, Santiago U, Zou H, Cai C, Sharma V, Guan Y, McCarl LH, Ma J, Wu YL, Michel J, Shi Y, Konnikova L, Amankulor NM, Zinn PO, Kohanbash G, Agnihotri S, Lu S, Lu X, Sun D, Gittes GK, Wang Q, Xiao X, Yimlamai D, Pollack IF, Camacho CJ, Hu B#. Chitinase-3-like-1 protein complexes modulate macrophage-mediated immune suppression in glioblastoma. J Clin Invest. 2021 Aug 16;131(16): e147552. doi: 10.1172/JCI147552.
Oh H, Hwang I, Jang JY, Wu L, Cao D, Yao J, Ying H, Li JY, Yao Y, Hu B, Wang Q, Zheng H, Paik J. Therapy-induced transdifferentiation promotes glioma growth independent of EGFR signaling. Cancer Res. 2021 Jan 28: canres.1810.2020. doi: 10.1158/0008-5472.CAN-20-1810.
Luo L, Guan X, Begum G, Ding D, Gayden J, Hasan MN, Fiesler VM, Dodelson J, Kohanbash G, Hu B, Amankulor NM, Jia W, Castro MG, Sun B, Sun D. Blockade of Cell Volume Regulatory Protein NKCC1 Increases TMZ-Induced Glioma Apoptosis and Reduces Astrogliosis. Mol Cancer Ther. 2020 Jul;19(7):1550-1561. doi: 10.1158/1535-7163.MCT-19-0910.
Koncar RF, Dey BR, Stanton AJ, Agrawal N, Wassell ML, McCarl LH, Locke AL, Sanders L, Morozova-Vaske O, Myers MI, Hamilton RL, Carcaboso AM, Kohanbash G, Hu B, Amankulor NM, Felker J, Kambhampati M, Nazarian J, Becher OJ, James CD, Hashizume R, Broniscer A, Pollack IF, Agnihotri S. Identification of Novel RAS Signaling Therapeutic Vulnerabilities in Diffuse Intrinsic Pontine Gliomas. Cancer Res. 2019 Aug 15;79(16):4026-4041. doi: 10.1158/0008-5472.
Shingu T, Ho A, Yuan L, Zhou X, Dai C, Zheng S, Wang Q, Zhong Y, Chang, Q, Horner J, Liebelt BD, Yao Y, Hu B, Chen Y, Fuller GN, Verhaak RGW, Heimberger AM, Hu J. QKI deficiency maintains stemness of glioma stem cells in suboptimal environment by downregulating endolysosomal degradation. Nature Genetics, 2017 49 (1):75–86.
Ong DST, Hu B*, Ho YW, Sauve, GC, Bristow CA, Wang Q, Multani SA, Chen P, Nezi L, Jiang S, Gorman CE, Monasterio, MM, Koul D, Marchesini M, Colla S, Jin EJ, Sulman EP, Lang FF, Spring DJ, Yung AW, Verhaak RGW, Chin L, Wang YA, and DePinho RA. PAF promotes stemness and radioresistance of glioma stem cells. Proc Natl Acad Sci USA, 2017 114 (43) E9086-E9095.
Wang Q, Hu B*, Hu X, Kim H, Squatrito M, Scarpace L, deCarvalho AC, Lyu S, Li P, Li Y, Barthel F, Cho HJ, Lin YH, Satani N, Martinez-Ledesma E, Zheng S, Chang E, Sauvé CG, Olar A, Lan ZD, Finocchiaro G, Phillips JJ, Berger MS, Gabrusiewicz KR, Wang G, Eskilsson E, Hu J, Mikkelsen T, DePinho RA, Muller F, Heimberger AB, Sulman EP, Nam DH, Verhaak RGW. Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. Cancer Cell, 2017 Jul 10;32(1):42-56.
Hu B, Wang Q, Wang YA, Hua S, Sauve, GC, Ong DS, Zheng, DL, Chang Q, Ho YW, Monasterio, MM, Lu,X, Zhong Y, Zhang J, Deng P, Tan Z, Wang G, Liao, W, Corley LJ, Yan H, Zhang J, You, Y, Liu N, Cai L, Finocchiaro G, Phillips JJ, Berger MS, Spring DJ, Hu J, Sulman EP, Fuller GN, Chin L, Verhaak RGW, DePinho RA. Epigenetic activation of WNT5A drives glioblastoma stem cell differentiation and invasive growth. Cell, 2016,167 (5):1281-1295.
Hu J, Ho AL, Yuan L, Hu B, Hua S, Hwang SS, Zhang J, Hu T, Zheng H, Gan B, Wu G, Wang YA, Chin L, DePinho RA. From the Cover: Neutralization of terminal differentiation in gliomagenesis. Proc Natl Acad Sci USA. 2013 110(36):14520-7.
Chen AJ, Paik JH, Zhang H, Shukla SA, Mortensen R, Hu J, Ying H, Hu B, Hurt J, Farny N, Dong C, Xiao Y, Wang YA, Silver PA, Chin L, Vasudevan S, Depinho RA. STAR RNA-binding protein Quaking suppresses cancer via stabilization of specific miRNA. Genes Dev. 2012 26(13):1459-72.
Muller FL, Colla S, Aquilanti E, Manzo VE, Genovese G, Lee J, Eisenson D, Narurkar R, Deng P, Nezi L, Lee MA, Hu B, Hu J, Sahin E, Ong D, Fletcher-Sananikone E, Ho D, Kwong L, Brennan C, Wang YA, Chin L, DePinho RA. Passenger deletions generate therapeutic vulnerabilities in cancer. Nature. 2012 488(7411):337-42.
Hu B, Gilkes DM, Chen J. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX. Cancer Res. 2007 67(18):8810-7.
Hu B, Gilkes DM, Farooqi B, Sebti SM, Chen J. MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. J Biol Chem. 2006 281(44):33030-5.
